Device Trial Radar · NCT00573586
Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada
Last checked: Nov 20, 2026Latest source record: May 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 2020
Primary completion
Dec 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- SonaCare MedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 14, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Male only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigational study on the use of high intensity focused ultrasound (HIFU) in the management of localized prostate cancer (T1c/T2a) as a primary non-comparative study. High intensity focused ultrasound (HIFU) is a non-invasive acoustic ablation technique that uses intersecting, precision focused ultrasound waves to raise the temperature of the target to) 80-90 degrees C in 2-3 seconds, destroying the targeted tissues (prostate cancer). The tissue targeting is highly precise, minimizing collateral damage. The overall hypothesis is that HIFU with Sonablate can safely, effectively and selectively ablate prostate cancer tissue, resulting in complete tissue necrosis, in patients diagnosed with localized T1c/T2a prostate cancer, with minimal morbidity. The specific hypothesis is that the Sonablate has the ability to: * Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to \<0.5ng/ml. * Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir) * Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects
Conditions
- Prostate Cancer
Interventions
Sonablate 500 (SB-500)Device
Sonablate 500 (SB-500)
Primary outcomes
What the sponsor says the trial is designed to measure.
- PSA levelTime frame: PSA level at 30 and 90 days post treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Abbotsford Regional Hospital Cancer Center
Abbotsford British Columbia, British Columbia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.